BC Extra | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BC Innovations | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Week In Review | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

Lilly sold Chinese rights to Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm for $375 million in a deal slated to close late 2019 or early 2020....
BC Innovations | Mar 13, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PHLDA1 could help predict resistance to RTK inhibitors in endometrial, breast and other cancers. In tumor samples from patients with metastatic breast cancer or locally advanced non-metastatic renal cancer...
BC Week In Review | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

On Nov. 7, EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China....
BC Extra | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma, a...
BC Week In Review | Sep 8, 2017
Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
BC Extra | Sep 8, 2017
Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
BC Innovations | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2 -amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher...
Items per page:
1 - 10 of 47
BC Extra | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

Kodiak in $225M royalty deal with Baker Bros. Kodiak Sciences Inc. (NASDAQ:KOD) gained $21.45 (72%) to $51.05 on Monday after selling royalty rights on global net sales of retinal vascular disease drug KSI-301 to Baker...
BC Innovations | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Week In Review | Apr 26, 2019
Company News

Lilly divests China rights to legacy antibiotics to Eddingpharm

Lilly sold Chinese rights to Vancocin vancomycin and Ceclor cefaclor, as well as a Ceclor manufacturing plant in Suzhou, to Eddingpharm for $375 million in a deal slated to close late 2019 or early 2020....
BC Innovations | Mar 13, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PHLDA1 could help predict resistance to RTK inhibitors in endometrial, breast and other cancers. In tumor samples from patients with metastatic breast cancer or locally advanced non-metastatic renal cancer...
BC Week In Review | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

On Nov. 7, EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China....
BC Extra | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led by new investor Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma, a...
BC Week In Review | Sep 8, 2017
Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
BC Extra | Sep 8, 2017
Company News

Lilly revamping presence in China

As part of an evolving research strategy in China, Eli Lilly and Co. (NYSE:LLY) will close its R&D center in Shanghai and instead seek to expand partnerships with local biotechs and academics. Spokesperson Lauren Zierke...
BC Innovations | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2 -amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher...
Items per page:
1 - 10 of 47